Horizon Pharma RAYOS (prednisone) delayed-release tablets have received the US Food and Drug Administration (FDA) approval. The approved drug is used to treat rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis ...
Tags: Horizon Pharma RAYOS delayed-release tablets, rheumatoid arthritis, RA
Volcano, a manufacturer of precision guided therapy tools, has entered into an agreement to buy US-based Crux Biomedical for $36m in cash. Crux Biomedical's product includes the Crux VCF system, an inferior vena cava (IVC) filter, which ...
Tags: precision guided therapy tools, buy.Crux Biomedical, Crux VCF system
Inhaled nitric oxide drug products developer GeNO has received four additional US patents on its proprietary inhaled nitric oxide (NO) generation chemistry and delivery technology, bringing the total number of US patents to sixteen. The ...
Tags: inhaled nitric oxide drug, NO, NO2, GeNO
Janssen Research & Development has submitted supplemental New Drug Applications (sNDAs) to the US Food and Drug Administration (FDA) for the use of Xarelto (rivaroxaban), an oral anticoagulant. Janssen said the drug is used to treat ...
Tags: Xarelto, rivaroxaban, DVT, pulmonary embolism, VTE
Janssen-Cilag International has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking conditional approval to use the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as ...
Tags: investigational drug bedaquiline, multi-drug resistant tuberculosis
The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to SkyePharma for a patent application 2012/0177734 of RAYOS (Prednisone) delayed-release tablets. The NOA covers the FDA-approved RAYOS, which uses the ...
Tags: SkyePharma, RAYOS delayed-release tablets, rheumatoid arthritis
Sosei Group Corporation,Japan, has received a positive opinion for its Seebri Breezhaler (glycopyrronium bromide/NVA237),a type of bronchodilator, from European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). ...
Tags: Seebri Breezhaler, bronchodilator, CHMP, Positive Chmp Opinion
MedQIA, a global Imaging CRO, has developed a new software toolkit of image analysis routines which employs a model-based engine to segment the lung, lobes, segments, and airways. The toolkit forms the basis of an Imaging Biomarker ...
Tags: MedQIA, global Imaging CRO, toolkit of image analysis routines
Janssen Research & Development company has submitted bedaquiline (TMC207) new drug application (NDA) to the US Food and Drug Administration (FDA) for approval. Bedaquiline,an investigational drug administered orally,is used as part of ...
Tags: FDA, new drug application, investigational drug, pulmonary
InterMune has completed divestiture of Actimmune (interferon gamma-1b) to Vidara Therapeutics, a part of an international specialty pharmaceutical group of companies with operations in Ireland and the US. Gross proceeds from the sale ...
Tags: Actimmune, interferon gamma-1b, esbriet, pirfenidone
UK based Prosonix has signed a collaborative research agreement with Imperial College London to accelerate the development of engineered multi-component particles (MCPs) as respiratory medicines. As part of the collaboration, Prosonix ...
Tags: collaborative research agreement, multi-component particles
Fresenius Kabi USA has announced the availability of Acetylcysteine Solution, USP, 20% 30ml vial for inhalation (mucolytic agent) or oral administration (acetaminophen antidote) to treat lung diseases. Acetylcysteine Solution, USP, ...
Tags: Acetylcysteine Solution, lung diseases, critical care products
Pulmatrix has demonstrated iSPERSE capabilities for inhaled dry powder delivery of antibiotics, antibodies and other macromolecules. These preclinical data demonstrated the ability of iSPERSE formulations to deliver stable and ...
Insmed has dosed first Cystic Fibrosis (CF) patient in the Clinical Evaluation of ARIKACE (CLEAR-108) phase 3 study of Arikace (liposomal amikacin for inhalation) in Europe. CLEAR-108 is a 300-patient randomized phase 3 trial comparing ...
Tags: Study of Arikace, pulmonary function, open-label safety study
Aptar Pharma, a subsidiary of Aptargroup, has named Jean-Marc Pardonge as the new president for the company's prescription division. The company is involved in developing and manufacturing nasal and pulmonary drug delivery devices. In ...
Tags: nasal and pulmonary drug, Pardonge's knowledge, pharmaceutical market